- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07603700
STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism (STRATEGY-PE)
Real-World Comparative Effectiveness and Safety of Anticoagulation, Thrombolysis, and Mechanical Thrombectomy in Intermediate-Risk Acute Pulmonary Embolism: A Multicenter Prospective Cohort Study
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Background: Acute pulmonary embolism (PE) is a severe manifestation of venous thromboembolism (VTE). Intermediate-high risk PE accounts for 20-30% of all PE cases with significant mortality driven by right ventricular (RV) dysfunction. Current guidelines recommend anticoagulation for all, with thrombolysis or mechanical thrombectomy as rescue or alternative therapies. However, there is significant heterogeneity in real-world treatment selection and a lack of head-to-head comparative evidence among the three strategies in complex real-world populations.
Objective: To compare the 30-day and 90-day all-cause mortality and 48-hour RV/LV ratio improvement rate among three treatment strategies (Anticoagulation, Thrombolysis, Mechanical Thrombectomy) in patients with intermediate-high risk acute PE.
Design: This is a prospective, multicenter, non-randomized, pragmatic cohort study. Treatment allocation is based on routine clinical decision-making (natural allocation) without investigator intervention. Advanced statistical methods (Propensity Score Matching/Weighting, Instrumental Variable analysis) will be used to control for confounding factors.
Participants: 1,300 patients with confirmed acute intermediate-high risk PE (RV/LV ratio ≥0.9 and elevated cardiac biomarkers, hemodynamically stable). There are no age limits to reflect real-world diversity.
Interventions/Exposures:
- Anticoagulation (AC): Standard anticoagulant therapy (LMWH, DOAC, UFH, or Warfarin).
- Thrombolysis (TL): Systemic thrombolysis or Catheter-Directed Thrombolysis (CDT) using agents like Urokinase, Alteplase, etc.
- Mechanical Thrombectomy (MT): Mechanical removal of thrombus using FDA/NMPA approved devices (e.g., Indigo, FlowTriever, Acoscream), with or without adjunctive anticoagulation/thrombolysis.
Outcomes:
- Primary: 30-day and 90-day all-cause mortality; 48-hour RV/LV ratio improvement rate (≥15% reduction).
- Secondary: Clinical deterioration, major bleeding (ISTH/GUSTO/BARC), functional status (6MWT, NYHA, PVFS), quality of life (PEmb-QoL, EQ-5D-5L), PE recurrence, and healthcare resource utilization.
Follow-up: Patients will be followed at 48 hours, 7 days, 30 days, and 90 days.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: he xu Dr, doctor
- Telefonnummer: +86 153 6611 0045
- E-post: kilogram@163.com
Studiesteder
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210006
- Nanjing First Hospital
-
Ta kontakt med:
- Interventional Vascular Department Director, doctor
- Telefonnummer: +86-25-52271000
- E-post: kilogram@163.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Age unlimited (reflecting real-world population).
- Symptom duration of acute PE ≤ 14 days.
- Confirmed acute PE by CTPA involving main or lobar pulmonary arteries.
- Defined as Intermediate-High Risk PE meeting all of the following:
- RV/LV ratio ≥ 0.9 (by CT or Echocardiography).
- Elevated cardiac biomarkers (Troponin > 99th percentile or BNP > 100 pg/mL).
- Hemodynamically stable (SBP ≥ 90 mmHg, no vasopressors required).
- Able to provide informed consent and complete follow-up.
Exclusion Criteria:
- Already received thrombolysis or mechanical thrombectomy for the current episode prior to enrollment.
- Unable to obtain baseline or follow-up CTPA imaging.
- (Note: Unlike strict RCTs, patients with cancer, renal insufficiency, or advanced age are NOT excluded to ensure real-world representativeness).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Anticoagulation Cohort
Patients receiving standard anticoagulation therapy alone without thrombolysis or mechanical thrombectomy.
|
Low Molecular Weight Heparin (LMWH), Direct Oral Anticoagulants (DOAC), Unfractionated Heparin (UFH), or Warfarin according to guideline-standard regimens.
Andre navn:
|
|
Thrombolysis Cohort
Patients receiving systemic thrombolysis or catheter-directed thrombolysis.
|
Any FDA/NMPA approved mechanical thrombectomy device (e.g., Indigo, FlowTriever, Acoscream) used for clot removal.
Andre navn:
|
|
Mechanical Thrombectomy Cohort
Patients undergoing mechanical thrombectomy procedures using percutaneous devices.
|
Urokinase, Pro-urokinase, Alteplase, or Tenecteplase administered systemically or via catheter.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
All-Cause Mortality at 30 Days
Tidsramme: 30 days
|
The percentage of participants who die from any cause within 30 days of enrollment.
|
30 days
|
|
All-Cause Mortality at 90 Days
Tidsramme: 90 days
|
The percentage of participants who die from any cause within 90 days of enrollment.
|
90 days
|
|
Right Ventricular to Left Ventricular (RV/LV) Ratio Improvement Rate at 48 Hours
Tidsramme: 48 hours ± 6 hours
|
The proportion of participants with a reduction in RV/LV ratio ≥15% from baseline measured by CTPA or Echocardiography.
|
48 hours ± 6 hours
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Major Bleeding Events
Tidsramme: 48 hours, 7 days, 30 days, 90 days
|
Incidence of major bleeding defined by ISTH, GUSTO, or BARC criteria (including intracranial hemorrhage).
|
48 hours, 7 days, 30 days, 90 days
|
|
Clinical Deterioration
Tidsramme: 48 hours, 7 days
|
Composite of hemodynamic instability, need for rescue therapy (escalation to thrombolysis/MT/ECMO), intubation, or PE-related death.
|
48 hours, 7 days
|
|
6-Minute Walk Test (6MWT) Distance
Tidsramme: 30 days, 90 days
|
Change in walking distance from baseline (estimated) to follow-up.
Minimal Clinically Important Difference (MCID) ≥30 meters.
|
30 days, 90 days
|
|
Post-VTE Functional Status (PVFS) Score
Tidsramme: 30 days, 90 days
|
Assessment of functional limitation due to VTE (Scale 0-5).
|
30 days, 90 days
|
|
Quality of Life (PEmb-QoL)
Tidsramme: 90 days
|
The questionnaire consists of 9 questions containing 40 items, which are organized into 6 domains: Frequency of Complaints (FC): Assesses the frequency of respiratory and general symptoms (e.g., dyspnea, chest pain). Daily Activity Limitations (AL): Measures limitations in performing activities of daily living (ADL). Work-related Problems (WP): Evaluates difficulties in performing work or school duties. Social Limitations (SL): Assesses restrictions on social activities. Intensity of Complaints (IC): Measures the severity of pain and breathlessness. Emotional Complaints (EC): Captures anxiety, frustration, and fear related to the disease. |
90 days
|
|
Symptomatic PE Recurrence
Tidsramme: 90 days
|
Confirmed recurrent PE via CTPA or V/Q scan.
|
90 days
|
|
ICU Length of Stay
Tidsramme: From ICU admission to ICU discharge, assessed up to 30 days
|
Duration of intensive care unit stay during the index hospitalization
|
From ICU admission to ICU discharge, assessed up to 30 days
|
|
Total Hospital Length of Stay
Tidsramme: From hospital admission to hospital discharge, assessed up to 90 days
|
Duration of index hospitalization from emergency department admission to hospital discharge
|
From hospital admission to hospital discharge, assessed up to 90 days
|
|
Total Medical Costs
Tidsramme: Through 90 days
|
Direct medical costs incurred during index hospitalization and within 90 days of enrollment, including medications, procedures, and hospitalization
|
Through 90 days
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Biomarker Improvement (Troponin, BNP, D-Dimer)
Tidsramme: 48 hours, 7 days
|
Percentage reduction in cardiac biomarkers and D-Dimer levels.
|
48 hours, 7 days
|
|
Daily Step Count
Tidsramme: Continuous monitoring through 90 days
|
Average daily step count measured by smart band (e.g., Xiaomi/Huawei/Apple Watch) during the 90-day follow-up period.
Assessed as a continuous variable (steps/day) and correlated with 6-Minute Walk Test distance and Post-VTE Functional Status score.
|
Continuous monitoring through 90 days
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Vaskulære sykdommer
- Kardiovaskulære sykdommer
- Sykdommer i luftveiene
- Lungesykdommer
- Embolisme og trombose
- Embolisme
- Tromboemboli
- Lungeemboli
- Venøs tromboembolisme
- Molekylære mekanismer for farmakologisk virkning
- Fibrinmodulerende midler
- Aminosyrer, peptider og proteiner
- Proteiner
- Svovelforbindelser
- Organiske kjemikalier
- Pyridiner
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Benzimidazoles
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Pyraner
- Farmakologiske handlinger
- Kjemiske handlinger og bruk
- Terapeutisk bruk
- Karbohydrater
- Hydrolaser
- Enzymer
- Enzymer og koenzymer
- Blodproteiner
- Heparin, lavmolekylvekt
- Glykosaminoglykaner
- Polysakkarider
- Morfoliner
- Oksaziner
- Tiophener
- Kumariner
- Benzopyraner
- Endopeptidaser
- Peptidhydrolaser
- Serine endopeptidaser
- Serinproteaser
- Plasminogenaktivatorer
- Blodkoagulasjonsfaktorer
- Kardiovaskulære midler
- 4-hydroxycoumarins
- Vevsplasminogenaktivator
- Hematologiske midler
- Rivaroksaban
- Dabigatran
- Tenecteplase
- Enoksaparin
- Warfarin
- Heparin
- Antikoagulanter
- Fibrinolytiske midler
- Apixaban
- Edoxaban
- Urokinase-Type Plasminogen Activator
Andre studie-ID-numre
- KY20260205-04
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
Tilgangskriterier for IPD-deling
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .